0001179110-22-002947.txt : 20220510 0001179110-22-002947.hdr.sgml : 20220510 20220510170503 ACCESSION NUMBER: 0001179110-22-002947 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220506 FILED AS OF DATE: 20220510 DATE AS OF CHANGE: 20220510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEVERINO MICHAEL CENTRAL INDEX KEY: 0001609447 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22910874 MAIL ADDRESS: STREET 1: 1 N. WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 edgar.xml FORM 4 - X0306 4 2022-05-06 0 0001551152 AbbVie Inc. ABBV 0001609447 SEVERINO MICHAEL 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 Vice Chairman Common Stock, $0.01 par value 2022-05-06 4 M 0 74309 54.44 A 226412 D Common Stock, $0.01 par value 2022-05-06 4 M 0 25691 54.86 A 252103 D Common Stock, $0.01 par value 2022-05-06 4 S 0 40176 150.10 D 211927 D Common Stock, $0.01 par value 2022-05-06 4 S 0 45988 151.13 D 165939 D Common Stock, $0.01 par value 2022-05-06 4 S 0 13836 151.78 D 152103 D Common Stock, $0.01 par value 2022-05-09 4 M 0 66299 54.86 A 218402 D Common Stock, $0.01 par value 2022-05-09 4 M 0 33701 58.88 A 252103 D Common Stock, $0.01 par value 2022-05-09 4 S 0 47215 149.53 D 204888 D Common Stock, $0.01 par value 2022-05-09 4 S 0 31714 150.63 D 173174 D Common Stock, $0.01 par value 2022-05-09 4 S 0 21071 151.42 D 152103 D Common Stock, $0.01 par value 2022-05-10 4 M 0 70779 58.88 A 222882 D Common Stock, $0.01 par value 2022-05-10 4 M 0 29221 61.36 A 252103 D Common Stock, $0.01 par value 2022-05-10 4 S 0 22873 151.16 D 229230 D Common Stock, $0.01 par value 2022-05-10 4 S 0 28536 152.24 D 200694 D Common Stock, $0.01 par value 2022-05-10 4 S 0 48591 152.83 D 152103 D Option (Right to Buy) 54.44 2022-05-06 4 M 0 74309 54.44 D 2015-06-02 2024-06-01 Common Stock 74309 0 D Option (Right to Buy) 54.86 2022-05-06 4 M 0 25691 54.86 D 2017-02-18 2026-02-17 Common Stock 25691 66299 D Option (Right to Buy) 54.86 2022-05-09 4 M 0 66299 54.86 D 2017-02-18 2026-02-17 Common Stock 66299 0 D Option (Right to Buy) 58.88 2022-05-09 4 M 0 33701 58.88 D 2016-02-19 2025-02-18 Common Stock 33701 70779 D Option (Right to Buy) 58.88 2022-05-10 4 M 0 70779 58.88 D 2016-02-19 2025-02-18 Common Stock 70779 0 D Option (Right to Buy) 61.36 2022-05-10 4 M 0 29221 61.36 D 2018-02-16 2027-02-15 Common Stock 29221 70879 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Steven L. Scrogham, attorney-in-fact for Michael Severino 2022-05-10